The end of a clinical trial is not a clean cut. Depending on how the trial went, you may face questions about ongoing access to a treatment that was working for you, or you may be transitioning back entirely to standard care. Understanding what to expect helps you plan that transition without gaps in your care.
The end-of-study visit
Most trials end with a final study visit — sometimes called a completion visit or end-of-treatment visit. This visit typically mirrors the first one in scope: vitals, blood draws, imaging, cognitive assessments, whatever was done at baseline. The purpose is to capture your final state and compare it to where you started.
After this visit, you'll have a follow-up period — often 30 to 90 days — during which the team may check in with you, call you to ask about any lingering effects, or schedule one more visit. This is the safety follow-up period, and it's important. Report anything unusual during this window, even if you think it's unrelated.
Access to the treatment after the trial
This is often the most pressing question for participants who felt the treatment was helping them. The answer depends on several factors: whether the trial succeeded, whether the drug is now in another trial or an extended access program, and whether it has received regulatory approval.
If the treatment showed strong results, there may be a compassionate use or expanded access program that allows continued access while the regulatory review process continues. Ask your study team specifically about this before the trial ends — not after. The options narrow once the formal study period closes.
If the treatment didn't show sufficient efficacy or was discontinued for safety reasons, access will end. This is the harder scenario. Discuss with your regular doctor what the next step in your care looks like, ideally while you're still enrolled and your care is partly covered by the trial.
What happens to your data
Your anonymized data becomes part of the research record. It goes into the sponsor's regulatory submission, may be published in academic journals, and contributes to the evidence base for the treatment. Even if the treatment ultimately didn't work, your data has value — it saves future patients from going through the same trial.
You won't usually be notified each time your data is used, but many trials commit to informing participants of the overall results. Ask the study team what their policy is on communicating outcomes to participants. Some send summary letters; others post results to ClinicalTrials.gov.
Returning to standard care
For most participants, the end of a trial means returning fully to standard care managed by your regular doctor. Make sure there's no gap. Schedule an appointment with your doctor before or shortly after your final study visit so your care is continuous. Bring any documentation the trial gave you — a treatment summary, an adverse events log — since your regular team will need to know what happened during the trial.
Finding out what the trial discovered
Results from clinical trials are required to be published in public registries within 12 months of study completion in many jurisdictions. You can find results for most US trials on ClinicalTrials.gov by searching for the trial's NCT number (listed in your consent form). European trials post results in EUCTR.
Reading the results of a study you participated in is something many participants want to do but don't realize they can. You contributed to that knowledge. You're entitled to see what it found.
Medical Disclaimer: This guide covers general post-trial processes. Your specific trial protocol governs what happens after completion. Always consult your healthcare provider for ongoing care decisions.